Share Email Print
cover

Proceedings Paper

Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance
Author(s): Joshua J. Souchek; Lindsey Muraskin; Lucas Houser; Quyen Vu; Aaron M. Mohs
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Aberrant metabolism mechanisms are a well-established hallmark of cancer. Exploiting tumor metabolism as a therapeutic target is being actively pursued. De novo synthesis of fatty acids by fatty acid synthase (FASN) is a particularly attractive mechanism to target because increased lipid synthesis is associated with more aggressive tumor. In particular, our work focuses on the reformulation of orlistat, an FDA-approved lipase inhibitor that also inhibits the thioesterase domain of FASN. We report on the rationale, synthesis, efficacy, delivery, and limitations of a novel nanoparticle formulation of orlistat in the goal of targeting the FASN pathway.

Paper Details

Date Published: 28 February 2019
PDF: 9 pages
Proc. SPIE 10859, Visualizing and Quantifying Drug Distribution in Tissue III, 1085909 (28 February 2019); doi: 10.1117/12.2512244
Show Author Affiliations
Joshua J. Souchek, Univ. of Nebraska Medical Ctr. (United States)
Lindsey Muraskin, Univ. of Nebraska Medical Ctr. (United States)
Lucas Houser, Univ. of Nebraska Medical Ctr. (United States)
Quyen Vu, Univ. of Nebraska Medical Ctr. (United States)
Aaron M. Mohs, Univ. of Nebraska Medical Ctr. (United States)


Published in SPIE Proceedings Vol. 10859:
Visualizing and Quantifying Drug Distribution in Tissue III
Kin Foong Chan; Conor L. Evans, Editor(s)

© SPIE. Terms of Use
Back to Top